Citadel Advisors
MYOV

Citadel Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

Citadel Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,059
Closed -$2.7M – 16061
2022
Q4 		$2.7M Sell
100,059
-870,046
-90% -$22.9M ﹤0.01% 4926
2022
Q3 		$17.4M Buy
970,105
+1,409
+0.1% +$22.5K ﹤0.01% 2032
2022
Q2 		$12M Buy
968,696
+318,407
+49% +$3.51M ﹤0.01% 2443
2022
Q1 		$8.66M Buy
650,289
+426,569
+191% +$5.72M ﹤0.01% 3194
2021
Q4 		$3.48M Buy
223,720
+41,572
+23% +$794K ﹤0.01% 5038
2021
Q3 		$4.09M Buy
182,148
+2,951
+2% +$64.8K ﹤0.01% 4695
2021
Q2 		$4.08M Sell
179,197
-7,384
-4% -$155K ﹤0.01% 4885
2021
Q1 		$3.84M Sell
186,581
-210,294
-53% -$4.79M ﹤0.01% 4867
2020
Q4 		$11M Buy
396,875
+283,848
+251% +$5.53M ﹤0.01% 2519
2020
Q3 		$1.59M Sell
113,027
-357,924
-76% -$6.66M ﹤0.01% 5157
2020
Q2 		$9.71M Buy
470,951
+146,693
+45% +$2M ﹤0.01% 2253
2020
Q1 		$2.45M Buy
324,258
+306,835
+1,761% +$3.44M ﹤0.01% 3823
2019
Q4 		$271K Sell
17,423
-64,735
-79% -$653K ﹤0.01% 7755
2019
Q3 		$427K Sell
82,158
-114,087
-58% -$846K ﹤0.01% 7012
2019
Q2 		$1.78M Buy
+196,245
New +$2.93M ﹤0.01% 4717

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's MYOV Position: Q1 2023 in Review

Citadel Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 100,059 shares — an estimated $2.7M sold.

Citadel Advisors first reported a position in MYOV in Q2 2019 and held it in 15 quarters. The position peaked at $17.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • Citadel Advisors reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 100,059 Myovant Sciences Ltd. shares in Q1 2023, an estimated $2.7M.
  • Citadel Advisors first reported a position in Myovant Sciences Ltd. in Q2 2019 and held it in 15 quarters.
  • Citadel Advisors's Myovant Sciences Ltd. position peaked at $17.4M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.